Guido Freckmann1, Stephan Arndt2, Albrecht Fießelmann3, Gerhard Klausmann4, Kristina Pralle5, Thomas Künsting6, Bettina Petersen6. 1. 1 Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany. 2. 2 Praxiszentrum für Diabetologie und Endokrinologie, Rostock, Germany. 3. 3 Praxisgemeinschaft Spandau, Berlin, Germany. 4. 4 Clinical Research Centre for Hematology, Oncology and Diabetic Disease, Aschaffenburg, Germany and Gemeinschaftspraxis Drs. Klausmann, Aschaffenburg, Germany. 5. 5 Diabeteszentrum am Sophie-Charlotte Platz, Berlin, Germany. 6. 6 Roche Diabetes Care GmbH, Mannheim, Germany.
Abstract
BACKGROUND:Continuous subcutaneous insulin infusion (CSII) therapy is a valuable option especially for people with type 1 diabetes. Although insulin infusion sets (IIS) are essential components of most insulin pump systems, only few studies have been conducted on their performance and safety. In this study 2 IIS with soft cannulas were compared. METHODS: In an open-label, randomized, crossover, multicenter 8-week study 80 type 1 diabetic subjects on CSII (20-74 years, mean 46.5 ± 12.9 years, 58.8% male) were enrolled to evaluate the use of 2 IIS. The Accu-Chek®FlexLink Plus (FL Plus) and the Accu-Chek® FlexLink infusion set (FL) were used 4 weeks each under real-life conditions at home. All patients had to record details about every IIS change in a diary. Insertion-related pain was assessed by means of a visual analogue scale (VAS). RESULTS: The mean pain noted during insertion was similar for both IIS (VAS 6.1 ± 6.4 mm for the FL Plus and 5.8 ± 6.3 mm for the FL, P = .92). 20.0% of the 895 IIS changes with FL Plus and 16.0% of the 854 with FL were unplanned. During the 4243 patient days of the study, 13 patients had adverse events. Among these, 2 serious adverse events occurred. Both serious events and 1 nonserious adverse event were considered as related to the IIS. Of the patients, 18.7% had kinked cannulas. Most patients were satisfied with both IIS. CONCLUSION: Both IIS are safe and effective. The 2 IIS did not differ from each other with respect to pain observed during insertion.
RCT Entities:
BACKGROUND: Continuous subcutaneous insulin infusion (CSII) therapy is a valuable option especially for people with type 1 diabetes. Although insulin infusion sets (IIS) are essential components of most insulin pump systems, only few studies have been conducted on their performance and safety. In this study 2 IIS with soft cannulas were compared. METHODS: In an open-label, randomized, crossover, multicenter 8-week study 80 type 1 diabetic subjects on CSII (20-74 years, mean 46.5 ± 12.9 years, 58.8% male) were enrolled to evaluate the use of 2 IIS. The Accu-Chek® FlexLink Plus (FL Plus) and the Accu-Chek® FlexLink infusion set (FL) were used 4 weeks each under real-life conditions at home. All patients had to record details about every IIS change in a diary. Insertion-related pain was assessed by means of a visual analogue scale (VAS). RESULTS: The mean pain noted during insertion was similar for both IIS (VAS 6.1 ± 6.4 mm for the FL Plus and 5.8 ± 6.3 mm for the FL, P = .92). 20.0% of the 895 IIS changes with FL Plus and 16.0% of the 854 with FL were unplanned. During the 4243 patient days of the study, 13 patients had adverse events. Among these, 2 serious adverse events occurred. Both serious events and 1 nonserious adverse event were considered as related to the IIS. Of the patients, 18.7% had kinked cannulas. Most patients were satisfied with both IIS. CONCLUSION: Both IIS are safe and effective. The 2 IIS did not differ from each other with respect to pain observed during insertion.
Authors: Lutz Heinemann; G Alexander Fleming; John R Petrie; Reinhard W Holl; Richard M Bergenstal; Anne L Peters Journal: Diabetologia Date: 2015-03-18 Impact factor: 10.122
Authors: Jamie R Wood; Elaine C Moreland; Lisa K Volkening; Britta M Svoren; Deborah A Butler; Lori M B Laffel Journal: Diabetes Care Date: 2006-11 Impact factor: 19.112
Authors: Arianne C van Bon; Bruce W Bode; Caroline Sert-Langeron; J Hans DeVries; Guillaume Charpentier Journal: Diabetes Technol Ther Date: 2011-04-02 Impact factor: 6.118
Authors: Stuart A Weinzimer; Christine Ternand; Campbell Howard; Cheng-Tao Chang; Dorothy J Becker; Lori M B Laffel Journal: Diabetes Care Date: 2007-11-05 Impact factor: 19.112
Authors: William Whyte; Debkalpa Goswami; Sophie X Wang; Yiling Fan; Niamh A Ward; Ruth E Levey; Rachel Beatty; Scott T Robinson; Declan Sheppard; Raymond O'Connor; David S Monahan; Lesley Trask; Keegan L Mendez; Claudia E Varela; Markus A Horvath; Robert Wylie; Joanne O'Dwyer; Daniel A Domingo-Lopez; Arielle S Rothman; Garry P Duffy; Eimear B Dolan; Ellen T Roche Journal: Nat Commun Date: 2022-08-03 Impact factor: 17.694
Authors: Roy W Beck; Steven J Russell; Edward R Damiano; Firas H El-Khatib; Katrina J Ruedy; Courtney Balliro; Zoey Li; Peter Calhoun Journal: Diabetes Technol Ther Date: 2022-10 Impact factor: 7.337
Authors: Laurel H Messer; Bruce A Buckingham; Fran Cogen; Mark Daniels; Greg Forlenza; Rabab Z Jafri; Nelly Mauras; Andrew Muir; R Paul Wadwa; Perrin C White; Steven J Russell; Edward R Damiano; Firas H El-Khatib; Katrina J Ruedy; Courtney A Balliro; Zoey Li; Martin Chase Marak; Peter Calhoun; Roy W Beck Journal: Diabetes Technol Ther Date: 2022-10 Impact factor: 7.337
Authors: Daniel P Howsmon; Nihat Baysal; Bruce A Buckingham; Gregory P Forlenza; Trang T Ly; David M Maahs; Tatiana Marcal; Lindsey Towers; Eric Mauritzen; Sunil Deshpande; Lauren M Huyett; Jordan E Pinsker; Ravi Gondhalekar; Francis J Doyle; Eyal Dassau; Juergen Hahn; B Wayne Bequette Journal: J Diabetes Sci Technol Date: 2018-02-01
Authors: Ron Brazg; Satish K Garg; Anuj Bhargava; James R Thrasher; Kashif Latif; Bruce W Bode; Timothy S Bailey; Barry S Horowitz; Arvind Cavale; Yogish C Kudva; Kevin B Kaiserman; George Grunberger; John Chip Reed; Sarnath Chattaraj; Gina Zhang; John Shin; Vivian Chen; Scott W Lee; Toni L Cordero; Andrew S Rhinehart; Robert A Vigersky; Bruce A Buckingham Journal: Diabetes Technol Ther Date: 2022-03-24 Impact factor: 7.337